[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 1, 2004

Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”

Author Affiliations

Controversies Section Editor: Phil B. Fontanarosa, MD, Executive Deputy Editor.


Author Affiliation: Law Office of Joseph D. Piorkowski, Jr, and Georgetown University Law Center, Washington, DC.


Published online November 22, 2004 (doi:10.1001/jama.292.21.2655).

JAMA. 2004;292(21):2655-2657. doi:10.1001/jama.292.21.2655

JAMA has invited this response from Bayer Corporation to the article authored by Psaty et al (the “Article”), which appears on page 2622 in this issue. Although the Article is presented as a scientific review of facts, sections are copied verbatim from a report submitted by the lead author in a US lawsuit in which he served as a paid expert for the plaintiff. Moreover, the Article’s conclusions are based upon selected exhibits from another lawsuit in which another author (Dr Ray) submitted a report for plaintiffs. Bayer won that court case (as well as the only other cerivastatin cases that have gone to trial). At least 2 of the authors continue to participate in lawsuits against Bayer.

First Page Preview View Large
First page PDF preview
First page PDF preview